Notice Number: NOT-HL-19-681

Key Dates
Release Date:January 29, 2019

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in RFA-TR-19-003 "HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)".

The following sections of RFA-TR-19-003 have been modified (shown in italics):

Part 1. Overview Information

Components of Participating Organizations

National Center for Advancing Translational Sciences (NCATS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute on Drug Abuse (NIDA)
National Institute of Neurological Disorders and Stroke (NINDS)

National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.350, 93.846, 93.286, 93.865, 93.279, 93.121, 93.853, 93.233, 93.837, 93.838, 93.839, 93.840

Section VII. Agency Contacts

Scientific/Research Contact(s)

Martha S. Lundberg, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0513
Email: lundberm@nhlbi.nih.gov

Financial/Grants Management Contact(s)

Anthony Agresti
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8014
Email: agrestia@nhlbi.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Martha S. Lundberg, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0513
Email: lundberm@nhlbi.nih.gov